
Shares of Celcuity Inc (NASDAQ:CELC) rose sharply in pre-market trading after the company announced it will disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.
Celcuity jumped 12.6% to $15.50 in the pre-market trading session.